Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 594.80K | 676.20K | 645.60K | 571.10K | 438.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 594.80K | 676.20K | 645.60K | 571.10K | 438.30K |
| Cost of Revenue | 198.40K | 230.00K | 246.30K | 226.80K | 189.30K |
| Gross Profit | 396.40K | 446.20K | 399.40K | 344.40K | 249.10K |
| SG&A Expenses | 1.28M | 2.21M | 2.24M | 2.34M | 2.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.48M | 2.44M | 2.48M | 2.57M | 2.35M |
| Operating Income | -887.00K | -1.77M | -1.84M | -2.00M | -1.91M |
| Income Before Tax | -1.39M | 2.08M | 2.94M | 2.57M | 8.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.39 | 2.08 | 2.94 | 2.57 | 8.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.39M | 2.08M | 2.94M | 2.57M | 8.18M |
| EBIT | -887.00K | -1.77M | -1.84M | -2.00M | -1.91M |
| EBITDA | -868.80K | -1.75M | -1.82M | -1.97M | -1.88M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 30.43B | 30.41B | 30.38B | 30.26B | 30.01B |
| Average Diluted Shares Outstanding | 30.43B | 53.88B | 61.86B | 61.74B | 68.63B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |